Literature DB >> 34664208

Droplet-Based Microfluidic Tool to Quantify Viscosity of Concentrating Protein Solutions.

Deyu Yang1, Maryam Daviran2, Kelly M Schultz2, Lynn M Walker3.   

Abstract

PURPOSE: Measurement of the viscosity of concentrated protein solutions is vital for the manufacture and delivery of protein therapeutics. Conventional methods for viscosity measurements require large solution volumes, creating a severe limitation during the early stage of protein development. The goal of this work is to develop a robust technique that requires minimal sample.
METHODS: In this work, a droplet-based microfluidic device is developed to quantify the viscosity of protein solutions while concentrating in micrometer-scale droplets. The technique requires only microliters of sample. The corresponding viscosity is characterized by multiple particle tracking microrheology (MPT).
RESULTS: We show that the viscosities quantified in the microfluidic device are consistent with macroscopic results measured by a conventional rheometer for poly(ethylene) glycol (PEG) solutions. The technique was further applied to quantify viscosities of well-studied lysozyme and bovine serum albumin (BSA) solutions. Comparison to both macroscopic measurements and models (Krieger-Dougherty model) demonstrate the validity of the approach.
CONCLUSION: The droplet-based microfluidic device provides accurate quantitative values of viscosity over a range of concentrations for protein solutions with small sample volumes (~ μL) and high compositional resolution. This device will be extended to study the effect of different excipients and other additives on the viscosity of protein solutions.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Concentration; High Compositional resolution; Microfluidics; Proteins; Viscosity

Mesh:

Substances:

Year:  2021        PMID: 34664208     DOI: 10.1007/s11095-021-03106-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Authors:  E Koren; L A Zuckerman; A R Mire-Sluis
Journal:  Curr Pharm Biotechnol       Date:  2002-12       Impact factor: 2.837

Review 2.  Challenges in the development of high protein concentration formulations.

Authors:  Steven J Shire; Zahra Shahrokh; Jun Liu
Journal:  J Pharm Sci       Date:  2004-06       Impact factor: 3.534

3.  Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations.

Authors:  Naoto Inoue; Eisuke Takai; Tsutomu Arakawa; Kentaro Shiraki
Journal:  Mol Pharm       Date:  2014-04-25       Impact factor: 4.939

Review 4.  Formulation and delivery issues for monoclonal antibody therapeutics.

Authors:  Ann L Daugherty; Randall J Mrsny
Journal:  Adv Drug Deliv Rev       Date:  2006-05-22       Impact factor: 15.470

5.  Characterization and suitability of therapeutic antibody dense phases for subcutaneous delivery.

Authors:  Harvey R Johnson; Abraham M Lenhoff
Journal:  Mol Pharm       Date:  2013-09-06       Impact factor: 4.939

6.  Hydrophobic salts markedly diminish viscosity of concentrated protein solutions.

Authors:  Wei Du; Alexander M Klibanov
Journal:  Biotechnol Bioeng       Date:  2010-11-17       Impact factor: 4.530

7.  Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions.

Authors:  Feng He; Christopher E Woods; Jennifer R Litowski; Lauren A Roschen; Himanshu S Gadgil; Vladimir I Razinkov; Bruce A Kerwin
Journal:  Pharm Res       Date:  2011-05-15       Impact factor: 4.200

Review 8.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.

Authors:  J L Cleland; M F Powell; S J Shire
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1993       Impact factor: 4.889

9.  Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.

Authors:  A Braun; L Kwee; M A Labow; J Alsenz
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

10.  Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection.

Authors:  Naoto Inoue; Eisuke Takai; Tsutomu Arakawa; Kentaro Shiraki
Journal:  J Biosci Bioeng       Date:  2013-11-20       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.